On May 7, JW Pharmaceutical announced its provisional results, reporting that standalone sales for the first quarter reached 183.5 billion KRW, a 3.0% increase compared to the same period last year.
During the same period, operating profit decreased by 15.4% to 22.6 billion KRW, mainly due to increased research and development (R&D) expenses. However, the operating margin remained in the double digits at 12.3%. Net profit for the period was 17.5 billion KRW, down 11.8%.
Sales in the prescription drug segment, which requires a doctor's prescription, totaled 152.2 billion KRW, representing 6.2% growth year-on-year. Livarozet, a treatment for dyslipidemia, achieved strong growth with sales of 23.4 billion KRW, up 35.1%. The Livaro product group, including the single-agent Livaro, Livarozet, and Livarov, recorded total sales of 45.5 billion KRW, an 18.4% increase.
Hemlibra, a treatment for hemophilia, and Actemra, a treatment for rheumatoid arthritis, recorded sales of 14.5 billion KRW and 6.0 billion KRW, respectively, representing year-on-year growth of 29.2% and 16.7%.
The infusion solution segment posted sales of 60.4 billion KRW, up 1.5% compared to the first quarter of last year. The high-value-added total parenteral nutrition solution product group, Winuf, grew by 11.6% to reach 20.2 billion KRW in sales. Basic infusion solutions recorded sales of 20.7 billion KRW, a 7.3% increase year-on-year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
